Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版

Ahead of print
Authors' Accepted
Current Issue
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us

Resources & Services

Email alert

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the

AJA Club (in English)
AJA Club (in Chinese)


Volume 17, Issue 6 (November 2015) 17, 923–924; DOI:10.4103/1008-682X.156852

Introduction of Dr. Andrew V Schally

Arturo Mendoza-Valdés

UROLOGO, Hospital Médica Sur, Puente de Piedra 150 T2-625, Col. Toriello Guerra, Tlalpan 14050 DF, Mexico

Correspondence: Dr. A Mendoza-Valdes (amendoza_valdes@hotmail.com)

23 June 2015


I first met Dr. Andrew V Schally (PhD, MDhc (Multi), DSc, Distinguished Medical Research Scientist, U.S. Department of Veterans Affairs Professor of Pathology and Department of Medicine,
Miller School of Medicine, University of Miami, Miami, Florida, USA) many years ago, probably around the beginning of the 1990's in one of his visits to Mexico City ([Figure 1]). He has many friends in my country since some of the investigations that led to the development of the LHRH agonists were made in a couple of Mexican hospitals in collaboration with some outstanding Mexican physicians that I will mention later. In that time, I was the head of the Department of Urology of the Mexican National Cancer Institute and our Director, Dr. Jaime de la Garza, invited him for a meeting. I was surprised by his humbleness, intelligence and easy going personality, in spite of being a Nobel Prize scientist.

Full Text | PDF |

Browse:  1844
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved